Pros and cons of treating murine myasthenia gravis with anti-C1q antibody

Erdem Tüzün, Jing Li, S. Shamsher Saini, Huan Yang, Premkumar Christadoss

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


To test the feasibility of classical complement pathway manipulation in experimental autoimmune myasthenia gravis (EAMG) treatment, C57BL/6 (B6) and RIIIS/J mice with EAMG were treated with 10 μg or 100 μg of anti-C1q Ab or isotype Ab. Treatment with 10 μg anti-C1q Ab significantly reduced the clinical severity, decreased lymph node cell IL-6 production and T cell populations. Conversely, administration of 100 μg anti-C1q Ab caused harmful side effects such as increased serum anti-acetylcholine receptor antibody, immune complex, C3 and lymph node B cell levels and kidney C3 and IgG deposits, which reduced the treatment efficacy.

Original languageEnglish (US)
Pages (from-to)167-176
Number of pages10
JournalJournal of Neuroimmunology
Issue number1-2
StatePublished - Jan 2007
Externally publishedYes


  • Autoimmunity
  • C1q
  • Classical complement pathway
  • Myasthenia gravis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Pros and cons of treating murine myasthenia gravis with anti-C1q antibody'. Together they form a unique fingerprint.

Cite this